- Shares of InSite Vision (INSV +23%) are sharply higher on the session.
- The company says top-line results from a Phase 3 study of BromSite in post-cataract surgery pain and inflammation show the treatment "achieved statistically significant superiority compared to vehicle."
- NDA filing expected next year. (PR)
InSite Vision rallies on Phase 3 read-out
Dec 18 2013, 10:25 ET